Table 1.

In vitro anti-proliferative effects of the obtained compounds against HepG2 and MCF-7 cell lines.

Comp. No.	X	HBA-HBD	R	In vitro IC50 (µM) a
				HepG2	MCF-7
12a	H	-NH-CO-		38.83 ± 3.2	33.27 ± 2.9
12b	Cl	-NH-CO-		64.16 ± 6.1	77.03 ± 7.3
12c	CH3	-NH-CO-		74.30 ± 6.8	36.72 ± 3.3
12d	H	-NH-CO-		23.61 ± 2.1	44.09 ± 3.8
12e	Cl	-NH-CO-		71.59 ± 6.7	62.29 ± 5.8
12f	CH3	-NH-CO-		36.96 ± 3.4	22.54 ± 1.8
12g	H	-NH-CO-		36.67 ± 2.9	53.01 ± 5.1
12h	Cl	-NH-CO-		102.10 ± 8.5	85.62 ± 8.2
12i	CH3	-NH-CO-		27.30 ± 2.2	27.99 ± 2.1
12j	H	-NH-CO-		50.92 ± 4.6	33.61 ± 2.8
12k	Cl	-NH-CO-		28.36 ± 2.5	86.62 ± 7.8
12l	CH3	-NH-CO-		10.50 ± 0.8	15.21 ± 1.1
13a	H	-CO -NH-NH-CO-		25.47 ± 2.1	32.47 ± 2.9
13b	Cl	-CO -NH-NH-CO-		42.06 ± 3.8	26.31 ± 2.2
13c	CH3	-CO -NH-NH-CO-		24.25 ± 2.1	53.13 ± 3.7
Sorafenib	-	-	-	5.57 ± 0.4	6.46 ± 0.3

^aData are presented as mean of the IC₅₀ values from three different experiments.